Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by grootvader2009on Mar 07, 2019 12:24pm

74 Views

Post# 29455965

RE:RE:RE:Form 45-106F1 Report of Exempt Distribution

10000 blocks for sale @3.02. 3.03. 3.05 on market depth
Scotia ITRADE gives a market depth with 5 levels on bid and ask.
Cant cut and paste like when I used to run the stock watch ticker.

My ticker is getting kind of old so I don’t need stockwatch to day trade anymore :>)

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages